Tracking Prescription Chemotherapy: Monthly Chemotherapy Rx Tracker: Basket TRx Growth +12% in 2Q26 vs. 11% in 1Q26; June Accelerated M/M But Note Potential Calendar Benefit

研报英文原文证据摘录

Tracking Prescription Chemotherapy: Monthly Chemotherapy Rx Tracker: Basket TRx Growth +12% in 2Q26 vs. 11% in 1Q26; June Accelerated M/M But Note Potential Calendar Benefit

ded only for distribution to wholesale clients under the

Corporations Act 2001 (Cth). UBS Switzerland AG is a related body corporate of UBS AG, Australia Branch and UBS Securities Australia Limited. This document may be

distributed to clients by those entities, but it is provided by UBS Switzerland AG and is not provided under any of the other entities’ AFSL. The information in this document

is general in nature and is not intended to address the objectives, financial situation or needs of any particular individual or entity. Each recipient should consider their own

objectives, financial situation or needs before acting on the advice and obtain the relevant Product Disclosure Statement (if required) before making any decision whether to

acquire any product. In Australia, UBS entities, other than UBS AG, Australia Branch, are not authorized deposit-taking institutions for the purposes of the Banking Act 1959

(Cth.) and their obligations do not represent deposits or other liabilities of UBS AG, Australia Branch. UBS AG, Australia Branch does not guarantee or otherwise provide

assurance in respect of the obligations of such UBS entities or the funds. An investor is exposed to investment risk including possible delays in repayment and loss of income

and principal invested, as relevant. If you do not wish to receive marketing materials from UBS, please contact your UBS representative or the contact details listed in the

Australia Privacy Notice: https://www.ubs.com/global/en/legal/privacy.html. Your personal data will be processed in accordance with this notice. Bahrain: This report is being